Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05514548Phase 2Completed

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Role: lead

NCT05891834Phase 2Completed

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Role: lead

NCT04531150Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Role: lead

NCT05282446Phase 1Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Role: lead

All 4 trials loaded